Percutaneous Revascularization for Stable Coronary Artery Disease Temporal Trends and Impact of Drug-Eluting Stents by Hilliard, Anthony A. et al.
CP
S
T
A
M
D
R
O
t
f
B
t
r
M
f
t
e
c
R
a
0
s
1
C
w
v
c
©
F
a
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 2 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 1 1 . 0 1 3LINICAL RESEARCH
ercutaneous Revascularization for
table Coronary Artery Disease
emporal Trends and Impact of Drug-Eluting Stents
nthony A. Hilliard, MD,* Aaron M. From, MD,* Ryan J. Lennon, MS,†
andeep Singh, MD, MPH,* Amir Lerman, MD,* Bernard J. Gersh, MB, CHB, DPHIL,*
avid R. Holmes, JR, MD,* Charanjit S. Rihal, MD,* Abhiram Prasad, MD*
ochester, Minnesota
bjectives We sought to determine the characteristics, outcomes, and temporal trends among pa-
ients undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD)
rom a single-center registry.
ackground There is controversy regarding the generalizability of the ﬁndings from randomized
rials of PCI for stable CAD to daily practice. An important perspective on the signiﬁcance of the trial
esults can be achieved by clearly documenting past and present practice of PCI.
ethods This was a retrospective analysis of 8,912 consecutive patients undergoing elective PCI
rom 1979 through 2006 at a tertiary referral center. Clinical, angiographic, and procedural charac-
eristics as well as in-hospital and long-term outcomes were measured in patients grouped into 4
ras depending on the dominant interventional strategy of that time: percutaneous transluminal
oronary angioplasty, early stent, bare-metal stent, and drug-eluting stent.
esults Procedural success rates have improved (81%, 92%, 96%, and 97%, respectively, p  0.001),
nd in-hospital mortality has decreased signiﬁcantly (1.0%, 0.8%, 0.1%, and 0.1%, respectively, p 
.001) over time. Kaplan-Meier estimates of mortality at 4 years were 11%, 13%, 10%, and 10%, re-
pectively (p  0.4). The 1-year target lesion revascularization rates in the 4 groups were 29%, 26%,
3%, and 8%, respectively (p  0.001).
onclusions Procedural success rates in contemporary practice of PCI for stable CAD are excellent
ith very low in-hospital mortality. Introduction of drug-eluting stents has reduced target lesion re-
ascularization but not mortality among all comers. Outcomes similar to that observed in recent
linical trials are being achieved in routine clinical practice. (J Am Coll Cardiol Intv 2010;3:172–9)
2010 by the American College of Cardiology Foundation
rom the *Division of Cardiovascular Diseases and Department of Internal Medicine, and the †Division of Biomedical Statistics
nd Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota.anuscript received August 11, 2009; revised manuscript received November 3, 2009, accepted November 18, 2009.
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173he practice of percutaneous revascularization for coronary
rtery disease (CAD) has evolved significantly over time as
consequence of numerous technical and pharmacological
dvances. These have resulted in an improvement in out-
omes and the ability to treat sicker patients as well as those
ith complex coronary morphology (1). Despite the in-
reasing role of coronary revascularization in patients with
cute coronary syndromes, stable CAD remains one of the
ost common indications for referral to the cardiac cathe-
erization laboratory (2). The relative merits of medical
herapy versus percutaneous coronary intervention (PCI) for
table CAD have been investigated in numerous clinical
rials (3–6). On the basis of the evidence, the current
merican College of Cardiology/American Heart Associa-
ion 2005 guidelines do not recommend PCI as the pre-
erred strategy but rather as a reasonable alternative to
edical therapy in selected patients (7).
The publication of the COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial has revitalized the debate regarding the precise
ole of PCI in stable CAD (8–12). The study indicated that
CI, in combination with optimal medical therapy, does
ot reduce long-term mortality and nonfatal myocardial
nfarction (MI) compared with optimal medical therapy
lone (13). The applicability and generalizability of these
ndings from a trial-based, highly selected population to
aily clinical practice remains to be determined. This is
specially so in light of the findings of the recent Japanese
table Angina Pectoris study that concluded that PCI was
uperior to medical therapy alone (14). Before widely
pplying the findings of the COURAGE trial, it is essential
o establish the characteristics of patients that are currently
eing referred for PCI in clinical practice, which we
ypothesized differ significantly from the trial cohort. Thus,
he aim of our study was to determine the characteristics,
utcomes, and temporal trends among consecutive patients
rom a single-center registry undergoing percutaneous cor-
nary revascularization for stable CAD.
ethods
ince 1979, patients undergoing percutaneous coronary
evascularization at the Mayo Clinic in Rochester, Minne-
ota have been prospectively followed in our registry, which
ncludes demographic, clinical, angiographic, and proce-
ural data. Immediate post-procedure and in-hospital
vents are recorded, and each patient is surveyed by tele-
hone with a standardized questionnaire at 6 months, 1
ear, and then annually after the procedure by trained data
echnicians. Ten percent of all records are randomly audited
y the supervisor for data integrity. All adverse events are
onfirmed by reviewing the medical records of the patients
ollowed at our institution and by contacting the patients’ thysicians and reviewing the hospital records of patients
reated elsewhere.
atients. The inclusion criterion was patients undergoing
lective PCI. Patients were excluded if they suffered an MI
n the 3 months before the PCI or declined authorization
llowing the use of their medical records for research. Of
atients with more than 1 qualifying procedure, only the
arliest was used. We identified 8,912 outpatients who met
hese criteria. The patients were grouped into 4 eras
ccording to the dominant interventional strategy at the
ime: Group 1 (October 1979 to December 1989, n 
,928) consisted of patients who principally underwent
ercutaneous transluminal coronary angioplasty (PTCA)
lone; Group 2 (January 1990 through December 1996, n
,806) consisted of patients from the early stent era in
hom stents were predominantly used as a bailout strategy;
roup 3 (January 1997 through March 2003, n  2,715)
ncluded patients from the bare-
etal stent (BMS) era in whom
tenting was the preferred strat-
gy in conjunction with dual oral
ntiplatelet therapy; and Group
(April 2003 through Decem-
er 2006, n  1,463) consisted
f patients whose PCI reflects
ontemporary practice and in-
ludes treatment with drug-
luting stent (DES). The study
as approved by the Institu-
ional Review Board.
eﬁnitions. The number of dis-
ased coronary arteries was de-
ned by the number of major
rteries with at least 70% steno-
is by visual assessment. Patients
ith 50% stenosis in the left
ain coronary artery were con-
idered to have 2-vessel disease if there was right dominance
nd 3-vessel disease if there was left dominance. Major
dverse cardiovascular events (MACE) were defined as 1 or
ore of the following: 1) in-hospital death; 2) Q-wave MI;
) urgent or emergent coronary artery bypass grafting
CABG) during the index hospital stay; and 4) cerebrovas-
ular accident defined as transient ischemic attack or stroke.
yocardial infarction was diagnosed in the presence of 2 of
he following 3 criteria: 1) typical chest pain for at least 20
in; 2) elevation of serum creatine kinase levels (or the MB
raction) 2 times normal; and 3) a new Q-wave on the
lectrocardiogram. In-hospital deaths included all deaths
uring the index hospital admission. Severe renal dysfunc-
ion was defined as a creatinine of 3.0 mg/dl or a history
f dialysis or renal transplant. Procedural success was
efined as a reduction of residual luminal diameter stenosis
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
DES  drug-eluting stent(s)
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PTCA  percutaneous
transluminal coronary
angioplasty
TLR  target lesion
revascularizationo 50% without in-hospital death, Q-wave MI, or need
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174or emergency CABG to allow comparison between the
TCA and stent eras. We also defined procedural success
or the BMS and DES eras as a reduction of residual
uminal diameter stenosis to 20% without in-hospital
eath, Q-wave MI, or need for emergency CABG. Long-
erm outcomes included all-cause mortality, combined end
oint of death or any MI, and target lesion revascularization
TLR). TLR was defined as any attempted percutaneous or
urgical revascularization of the target lesion after the initial
rocedure. Other procedural complications, such as those
elated to the vascular access site, were not included in the
resent analysis.
tatistics. Data are presented as the mean  SD or as a
requency (percentage). Kaplan-Meier methods were used
o estimate survival curves. Survival was analyzed in all
atients, with follow-up starting on the day of the PCI.
ests for trends across time groups were made with linear
ontrasts of means in a 1-way analysis of variance model for
umerical data (with square root transformation for ordinal
iscrete variables), the Armitage trend test for categorical
Table 1. Baseline Clinical Characteristic
1979–1989
(n  1,928)
19
(n
Age, yrs 62.5 10.6 64
Male 1,383 (72%) 2,0
Diabetes mellitus 263 (14%) 5
Hypertension 881 (46%) 1,4
Hyperlipidemia 698 (42%) 1,2
Smoking status
Never 704 (37%) 1,0
Former 854 (44%) 1,3
Current 365 (19%) 4
Body mass index, kg/m2 27.7 4.4 28
CCS severity
I 26 (1%)
II 378 (20%) 7
III 680 (35%) 8
IV 674 (36%) 8
Presentation without chest pain 138 (7%) 2
Positive stress test as the predominant indication for PCI 91 (5%) 1
Prior PCI 87 (5%) 3
Prior CABG 307 (16%) 6
Peripheral vascular disease 1
Cerebrovascular disease
Prior myocardial infarction 534 (28%) 9
Congestive heart failure 136 (7%) 2
Severe chronic renal failure NA
Ejection fraction, %
40 84 (4%) 1
40 1,491 (77%) 1,4
Missing data 353 (18%) 1,2
Values are mean SD or n (%). *The p value is test for trend across time groups; †p value is test ofCABG coronary artery bypass grafting; CCS Canadian Cardiovascular Society Angina Classification; Pata, and linear contrasts of group effects in a Cox propor-
ional hazards model for time-to-event data. To estimate
he adjusted effect of treatment era on long-term outcomes,
ox proportional hazards models were employed. Age, sex,
nd other covariates significantly different between the
roups were included as covariates for risk adjustment.
hese models were run on the subset of PCIs from 1994
nward, because earlier PCIs did not have complete data
ollection of some important risk factors.
esults
aseline characteristics. The clinical characteristics of the
atients in the 4 groups are summarized in Table 1. There
as been a significant and progressive increase in the number of
atients with comorbid conditions. The body mass index of the
atients has increased steadily, but the frequency of active
mokers has diminished. The prevalence of a reduced ejection
raction (40%), symptomatic congestive heart failure, and a
istory of prior PCI has also increased.
96
6)
1997–March 2003
(n  2,715)
April 2003–2006
(n  1,463) p Value* p Value†
.8 66.1 11.0 66.8 11.2 0.001 0.028
%) 2,000 (74%) 1,038 (71%) 0.59 0.06
%) 659 (24%) 454 (31%) 0.001 0.001
%) 1,773 (67%) 1,114 (79%) 0.001 0.001
%) 1,904 (76%) 1,180 (85%) 0.001 0.001
0.001 0.42
%) 992 (37%) 547 (39%)
%) 1,356 (51%) 688 (49%)
%) 333 (12%) 178 (13%)
8 29.5 5.5 30.0 5.8 0.001 0.004
0.001 0.001
) 60 (2%) 41 (3%)
%) 889 (33%) 467 (32%)
%) 966 (36%) 315 (22%)
%) 368 (14%) 107 (7%)
) 425 (16%) 528 (36%)
) 409 (15%) 446 (30%) 0.001 0.001
%) 697 (26%) 413 (28%) 0.001 0.07
%) 595 (22%) 333 (23%) 0.001 0.52
%) 295 (11%) 165 (12%) 0.76 0.60
) 283 (11%) 161 (11%) 0.007 0.51
%) 748 (28%) 377 (26%) 0.06 0.21
%) 247 (10%) 155 (11%) 0.001 0.10
) 78 (3%) 62 (4%) 0.31 0.018
0.001 0.75
) 232 (9%) 151 (10%)
%) 1,596 (59%) 880 (60%)
%) 887 (33%) 432 (30%)
ting versus bare-metal stent eras.90–19
 2,80
.8 10
97 (75
51 (20
70 (53
77 (52
46 (37
29 (48
18 (15
.4 4.
46 (2%
64 (27
91 (32
60 (31
44 (9%
74 (6%
91 (14
97 (25
15 (11
79 (8%
20 (33
65 (10
38 (4%
17 (4%
49 (52
40 (44
drug-eluCI percutaneous coronary intervention.
i
a
t
B
w
o
p
a
p
A
m
A
a
i
a
i
m
s
D
c
t
(
i
O
c
b
w
r
c
o
(
p
m
(
i
n
c
a
w
m
r
n
(
m
T
d
2
t
s
4
2
T
1
1
r
3
w
f
(
D
T
r
i
s
2
3
t
p
m
s
T
T
p
i
h
c
D
d
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 2 , 2 0 1 0 Hilliard et al.
F E B R U A R Y 2 0 1 0 : 1 7 2 – 9 PCI for Stable Disease
175Although chest pain has remained the predominant
ndication for PCI in all time periods, increasingly patients
re being referred for PCI on the basis of indications other
han angina, which in most cases is a positive stress test.
eta-blockers have become the preferred anti-anginal drug
ith decreasing use of nitrates and calcium channel blockers
ver time (Fig. 1). In the most recent cohort, 80% of
atients were treated with at least 1 anti-anginal medication
t the time of referral for PCI. An increasing proportion of
atients are on established aspirin therapy before PCI.
ngiographic and procedural characteristics. Table 2 sum-
arizes the angiographic and procedural characteristics.
pproximately one-half of patients had multivessel disease,
nd 50% of interventions were in the left anterior descend-
ng artery. There was no significant change in these char-
cteristics over time. The introduction of DES did not
ncrease in the frequency of multivessel PCI with the vast
ajority of PCI involving a single vessel. The number of
tents used per patient has remained similar in the BMS and
ES eras. There has been a trend toward treatment of more
omplex lesion morphology with increasing prevalence of
ype C lesions. The frequency of treatment of bifurcation
p  0.001) and calcified lesions (p  0.001) has increased
n the DES compared with the BMS eras.
utcomes. Despite the increase in lesion complexity, pro-
edural success has continued to improve and is significantly
etter (p  0.001) in the BMS and DES cohorts compared
ith the previous 2 cohorts (Table 3). This has been the
esult of a marked reduction in abrupt and subacute vessel
losure in the stent era, although the rate of branch vessel
cclusion remains unchanged.
Figure 1. Trends in Medical Therapy
Trends in medication use at the time of admission for percutaneous coro-
nary intervention (PCI). Data regarding lipid-lowering agents and angioten-
sin-converting enzyme (ACE) inhibitors were not available for the ﬁrstT
cohort.In-hospital mortality decreased over time and is very low
0.1%) in contemporary practice. There has also been a
rogressive decrease in Q-wave MI, but there has been a
inor but statistically significant increase in stroke rates
Table 3). There was also a marked decrease in the rate of
n-hospital CABG with the introduction of stents from
early 10% in the PTCA era to 0.3% in the current era.
Kaplan-Meier estimates for all-cause mortality and the
ombined end point of death or MI are shown in Figures 2A
nd 2B, respectively. Median follow-up (interquartile range)
as available for 230 (217 to 265) months, 158 (133 to 180)
onths, 77 (61 to 98) months, and 24 (11 to 36) months,
espectively, for the 4 groups. During follow-up, there was
o significant difference in the unadjusted mortality rates
p  0.41 for comparison between group). At 4 years, the
ortality rates were 11%, 13%, 10%, and 10%, respectively.
here was also no difference in the combined end point of
eath or MI (p  0.068) with event rates at 4 years of 21%,
3%, 19%, and 22%, respectively. The risk-adjusted mor-
ality and the combined end point of death or MI were not
ignificantly different in the stent eras. The TLR rates in the
groups were 24%, 21%, 10%, and 4% at 6-months and
9%, 26%, 13%, and 8%, respectively, at 1 year (p  0.001).
arget lesion redilation (repeat PCI) rates at 6 months were
0%, 14%, 6%, and 3%, respectively, and at 1-year were
4%, 18%, 9%, and 6%, respectively (p  0.001). Rates of
epeat target vessel redilation or CABG at 4 years were 38%,
4%, 21%, and 17%, respectively (p 0.001) (Fig. 2C). There
as a reduction in the prevalence of severe angina during
ollow-up. At 4 years, 58%, 55%, 67%, and 66%, respectively
p  0.001), were free of severe angina.
iscussion
he major findings of the present study among 8,912 patients
equiring elective PCI for stable CAD are that the procedures
n contemporary practice are generally performed: 1) for
ymptomatic patients who are receiving anti-anginal therapy;
) to treat a single vessel in approximately 80% of patients; and
) with a success rate of 97% and a mortality of 0.1%. Over
he past 27 years, PCI is increasingly being performed in
atients with greater comorbidities and more complex lesion
orphology but with markedly reduced rates of MACE. As
een in clinical trials, the introduction of DES has reduced
LR but not mortality or MI.
rends over time. In the present study, age as well as the
revalence of diabetes mellitus, hypertension, and hyperlip-
demia has increased steadily over each time period. This
as been accompanied by greater frequency of adverse lesion
haracteristics such as type C lesions and calcified lesions.
espite the higher risk setting, there has been over a 10-fold
ecrease in in-hospital mortality, Q-wave MI, and the need
or CABG when comparing the PTCA with the stent eras.
his is due, in part, to a reduction in angiographic complica-
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176ions such as abrupt closure, subacute vessel occlusion, and
oronary embolization that are most often due to dissection or
hrombus. As a consequence, procedural success rate has
ncreased from 81% to 97%. These findings reflect the numer-
us technical and pharmacological advances and greater oper-
tor expertise over time making it possible to offer percutane-
us revascularization to a broader patient population.
While in the PTCA era, procedures were invariably being
erformed for angina; in the DES era, angina is the
redominant symptom in approximately two-thirds of pa-
ients. The remainder was primarily referred because of the
resence of ischemia on a stress test. We speculate that there
ight be 2 reasons for the changing practice. First, there is an
ncreasing awareness of the importance of ischemia as a
rognostic marker. The efficacy of PCI in relieving ischemia
nd the potential for improving outcomes in selected patients
ith stable CAD has recently been demonstrated in a substudy
f the COURAGE (Clinical Outcomes Utilizing Revascular-
zation and Aggressive Drug Evaluation) trial and previously in
he ACIP (Asymptomatic Cardiac Ischemia Pilot) study
15,16). Second, there is increasing use of noninvasive tests to
iagnose CAD, for example, to risk stratify before noncardiac
Table 2. Angiographic and Procedural Characteristics
1979–1989
(n  1,928)
1990–1996
(n  2,806)
Number of vessels diseased
Single 995 (53%) 1,390 (51%)
Double 665 (35%) 949 (35%)
Triple 232 (12%) 385 (14%)
AHA lesion classiﬁcation
B1 406 (20%)
B2 760 (38%)
C 743 (37%)
Calciﬁcation 247 (13%) 1,029 (39%)
Bifurcation lesion 113 (12%)
Number of vessels treated
1 1,577 (82%) 2,347 (84%)
2 326 (17%) 434 (15%)
3 25 (1%) 25 (1%)
Total number of stent placed 0.0 0.0 0.4 0.8
Bare-metal stent use 2 (0%) 697 (25%)
Drug-eluting stent use 0 (0%) 0 (0%)
Vessel treated
Left anterior descending 998 (52%) 1,231 (44%)
Proximal left anterior descending 466 (24%) 485 (17%)
Circumﬂex 521 (27%) 763 (27%)
Right 650 (34%) 961 (34%)
Left main 16 (1%) 42 (1%)
Vein graft intervention 121 (6%) 308 (11%)
Values are n (%) or mean SD. *The p value is test for trend across time groups; †p value is for dru
AHA American Heart Association.urgery (17). Among those with angina, the majority of catients had moderate symptoms (Canadian Cardiovascular
ociety class II and III).
Over time, significant changes have occurred in the rates of
se of the various classes of anti-anginal therapy (Fig. 1). The
se of nitrates and calcium channel blockers has steadily
eclined, whereas the use of beta-blockers has increased in each
ubsequent cohort. In addition, the use of antiplatelet therapy,
ipid-lowering therapy, and angiotensin-converting enzyme
nhibitors has significantly increased over time. These trends in
edical therapy for stable CAD reflect the development of
videnced-based practice directed by national guidelines (18),
lthough there is significant potential for improvement, as
anifest by the fact that only 68% of patients were treated with
tatin 1 year after PCI in the DES cohort.
In the present study, the third cohort of 2,715 patients
rom the BMS era was contemporaneous to the enrollment
eriod of the COURAGE trial, which randomized 1,149
atients to PCI strategy. Compared with the PCI arm of
he trial, patients in routine clinical practice have more
dverse characteristics (Table 4). Use of medications for
econdary prevention was uniformly lower in the present
tudy, underscoring the fact that medical therapy in general
997–March 2003
(n  2,715)
April 2003–2006
(n  1,463) p Value* p Value†
0.22 0.001
1,267 (49%) 720 (56%)
899 (35%) 404 (32%)
398 (15%) 151 (12%)
0.015 0.43
495 (19%) 289 (20%)
993 (37%) 473 (33%)
1,069 (40%) 616 (43%)
1,000 (40%) 572 (47%) 0.001 0.001
331 (13%) 235 (17%) 0.001 0.001
0.015 0.91
2,198 (81%) 1,185 (81%)
472 (17%) 256 (18%)
45 (2%) 21 (1%)
1.4 1.1 1.5 1.0 0.001 0.81
2,362 (87%) 198 (14%) 0.001 0.001
0 (0%) 1,151 (79%)
1,245 (46%) 732 (50%) 0.39 0.009
506 (19%) 240 (16%) 0.001 0.07
775 (29%) 399 (27%) 0.50 0.39
962 (35%) 489 (33%) 0.74 0.20
47 (2%) 60 (4%) 0.001 0.001
233 (9%) 83 (6%) 0.22 0.001
g versus bare-metal stent eras.1
g-elutinlinical practice might be suboptimal when compared with
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177he case management approach of the clinical trial. In
ontrast, the procedural success rate was higher in the
resent study. Of note, the composite end point of death or
onfatal MI in the present study at 4 years was identical to
hat reported in the COURAGE trial at a median follow-up
f 4.5 years in the PCI arm of the trial. The mortality was
lso similar, as was the rate of repeat revascularization. Thus,
ur findings indicate that “COURAGE- like” results can be
chieved in clinical practice, despite the patients being older,
ith more adverse clinical characteristics, and receiving less
ntense medical therapy. This might, in part, reflect the higher
rocedural success rate in our registry (89% vs. 94%). It is
robable that outcomes would be even better if optimal
edical therapy—as administered in the COURAGE trial—
as used, but this would require additional resources to
stablish an intensive case management approach to secondary
revention that is not generally available.
omparison of outcomes in the BMS and DES eras. Random-
zed controlled trials (19,20–23) and observational studies
24) have demonstrated that BMS reduce the rates of TLR
ompared with PTCA. More recently, DES have been
hown to be superior to BMS with regard to reducing
estenosis and TLR (25–31). There is a paucity of data on the
mpact of DES, relative to BMS, on TLR rates and outcomes
fter PCI for stable CAD in clinical practice. Observational
tudies to date reporting experience from unrestricted consec-
tive patients have typically included heterogeneous popula-
ions of stable CAD and acute coronary syndrome with
ollow-up limited to 1 to 2 years (32–36).
The present study provides a unique perspective on PCI
or stable CAD from a single registry over 3 decades with
ong-term follow-up. At 1 year, we observed a 54% relative
eduction in clinically driven TLR in the BMS era com-
Table 3. In-Hospital Outcomes
1979–1989
(n  1,928)
1990–199
(n  2,806
Procedural success 1,566 (81%) 2,573 (91.7%
Procedural success (20% residual stenosis) — —
Complications
Branch vessel occlusion 37 (2.0%) 72 (2.6%)
Abrupt closure 77 (4.0%) 93 (3.3%)
Subacute vessel closure (24 h) 133 (7.0%) 122 (4.3%)
Coronary embolization 13 (0.7%) 56 (2.0%)
Death 19 (1.0%) 22 (0.8%)
Any myocardial infarction 112 (5.8%) 166 (5.9%)
Q-wave myocardial infarction 36 (1.9%) 29 (1.0%)
CABG 184 (9.5%) 70 (2.5%)
Stroke 0 (0.0%) 2 (0.1%)
MACE 105 (5.4%) 81 (2.9%)
Values are n (%). *The p value is test for trend across time groups; †p value is test for drug-eluting v
CABG coronary artery bypass grafting; MACEmajor adverse cardiac event.ared with the early stent era (Fig. 2C). There was a further t0% decrease in 1-year TLR rates with the introduction of
ES. Thus, contemporary rates of TLR at 1 year are 76%
ess compared with the PTCA era. These findings confirm
hat the benefits seen in the pivotal trials are being trans-
ated to clinical practice, despite the frequent “off-label use”
f the stents (37,38). Moreover, we demonstrate that the
enefit with regard to TLR is sustained over the entire
uration of follow-up, which in the case of BMS was 10
ears. In contrast, there has been no change in the unad-
usted rates of mortality or the combined end point of death
r MI in the DES era, compared with the BMS era (Figs.
A and 2B). These data must be interpreted with the
nowledge that there has been a marked change in patient
haracteristics and also pharmacological therapy for secondary
revention over the different time periods, making direct
omparison difficult and unreliable. To account for this fact,
isk-adjusted models for outcomes were analyzed but did not
emonstrate an independent impact of treatment era on
ortality or the combined end point of death or MI. It is
eassuring that over 4 years of follow-up DES use was not
ssociated with worse outcomes compared with BMS, given
he concerns over stent thrombosis with the newer stents (30).
ur finding that the introduction of BMS and DES have not
mproved survival in stable CAD is entirely consistent with the
ndings in the randomized trials (13,19,20,39–41).
tudy limitations. Although the data were collected pro-
pectively, this is a retrospective single-center analysis and is
ubject to the limitations of such analyses. Our registry did
ot record the occurrence of stent thrombosis during the
tudy period, and hence we cannot explore the impact of
ES on this phenomenon. The study is limited to patients
reated with PCI, and we cannot comment on the trends in
utcomes for patients who are managed with medical
1997–March 2003
(n  2,715)
April 2003–2006
(n  1,463) p Value* p Value†
2,615 (96.3%) 1,413 (96.6%) 0.001 0.66
2,542 (93.6%) 1,397 (95.5%) — 0.014
106 (3.9%) 30 (2.1%) 0.08 0.001
22 (0.8%) 10 (0.7%) 0.001 0.65
30 (1.1%) 13 (0.9%) 0.001 0.51
32 (1.2%) 6 (0.4%) 0.19 0.013
4 (0.1%) 1 (0.1%) 0.001 0.48
130 (4.8%) 53 (3.6%) 0.001 0.08
6 (0.2%) 2 (0.1%) 0.001 0.55
20 (0.7%) 5 (0.3%) 0.001 0.11
10 (0.4%) 3 (0.2%) 0.012 0.37
32 (1.2%) 9 (0.6%) 0.001 0.08
are-metal stent eras.6
)
)
ersus bherapy or surgical revascularization.
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178onclusions
lective PCI for stable CAD is being performed, as with other
Figure 2. Long-Term Mortality and Composite End Points of Death or MI
and Repeat Target Lesion Redilation or CABG
Kaplan-Meier curves showing survival free of (A) death, (B) death/myocar-
dial infarction (MI), and (C) target lesion redilation (T Redil)/coronary artery
bypass grafting (CABG). PCI  percutaneous coronary intervention.atient subsets, in increasingly older patients with more com-lex lesion morphology. The routine use of stents has greatly
educed complication and improved procedural success rates. It
s encouraging to note that outcomes in the BMS era were
imilar to those observed in the randomized COURAGE trial,
ven though our patients seemed to have more adverse char-
cteristics. The introduction of DES has been associated with
ower TLR without altering mortality or MI. Continued
urveillance is required to assess the long-term impact of DES
n mortality in large cohorts of patients.
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